Outlook Therapeutics (OTLK)
Market Price (2/12/2026): $0.474 | Market Cap: $22.4 MilSector: Health Care | Industry: Biotechnology
Outlook Therapeutics (OTLK)
Market Price (2/12/2026): $0.474Market Cap: $22.4 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -40% | Weak multi-year price returns2Y Excs Rtn is -133%, 3Y Excs Rtn is -167% | Penny stockMkt Price is 0.5 |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Retinal Disease Treatments, Targeted Therapies, and Biopharmaceutical R&D. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -67 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -4744% | |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 100% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 629% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -3667%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3667% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -286% | ||
| High stock price volatilityVol 12M is 123% | ||
| Key risksOTLK key risks include [1] its repeated failure to secure FDA approval for its lead drug candidate ONS-5010 and [2] severe financial distress that raises substantial doubt about its ability to continue as a going concern. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -40% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Retinal Disease Treatments, Targeted Therapies, and Biopharmaceutical R&D. |
| Weak multi-year price returns2Y Excs Rtn is -133%, 3Y Excs Rtn is -167% |
| Penny stockMkt Price is 0.5 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -67 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -4744% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 100% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 629% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -3667%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3667% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -286% |
| High stock price volatilityVol 12M is 123% |
| Key risksOTLK key risks include [1] its repeated failure to secure FDA approval for its lead drug candidate ONS-5010 and [2] severe financial distress that raises substantial doubt about its ability to continue as a going concern. |
Qualitative Assessment
AI Analysis | Feedback
Outlook Therapeutics (OTLK) stock has lost about 65% since 10/31/2025 because of the following key factors:
1. Persistent FDA Rejection of ONS-5010/Lytenava for Wet AMD
Outlook Therapeutics received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on December 31, 2025, regarding its Biologics License Application (BLA) for ONS-5010/Lytenava (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD). The FDA indicated that the additional data submitted did not sufficiently address previous concerns, reiterating the need for more evidence confirming efficacy. This marked the third time the company's application for its lead drug candidate was not approved, creating significant uncertainty about its path to U.S. market commercialization. Further news on January 6, 2026, confirmed this third CRL following a resubmission.
2. Weak Financial Performance and Mounting Losses
The company reported ongoing financial challenges, including significant negative earnings. For the period ending June 30, 2025, Outlook Therapeutics reported losses of approximately -$20.15 million and negative total equity of -$37.18 million. Reports from December 31, 2025, further highlighted that the firm's total liabilities exceeded its total assets, with a substantial EBITDA deficit and significant operating losses, casting doubt on the company's financial stability.
Show more
1. Persistent FDA Rejection of ONS-5010/Lytenava for Wet AMD
Outlook Therapeutics received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on December 31, 2025, regarding its Biologics License Application (BLA) for ONS-5010/Lytenava (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD). The FDA indicated that the additional data submitted did not sufficiently address previous concerns, reiterating the need for more evidence confirming efficacy. This marked the third time the company's application for its lead drug candidate was not approved, creating significant uncertainty about its path to U.S. market commercialization. Further news on January 6, 2026, confirmed this third CRL following a resubmission.
2. Weak Financial Performance and Mounting Losses
The company reported ongoing financial challenges, including significant negative earnings. For the period ending June 30, 2025, Outlook Therapeutics reported losses of approximately -$20.15 million and negative total equity of -$37.18 million. Reports from December 31, 2025, further highlighted that the firm's total liabilities exceeded its total assets, with a substantial EBITDA deficit and significant operating losses, casting doubt on the company's financial stability.
Show more
Stock Movement Drivers
Fundamental Drivers
The -62.7% change in OTLK stock from 10/31/2025 to 2/11/2026 was primarily driven by a -49.3% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2112026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.26 | 0.47 | -62.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 1 | -6.1% |
| P/S Multiple | 30.9 | 15.7 | -49.3% |
| Shares Outstanding (Mil) | 37 | 47 | -21.7% |
| Cumulative Contribution | -62.7% |
Market Drivers
10/31/2025 to 2/11/2026| Return | Correlation | |
|---|---|---|
| OTLK | -62.7% | |
| Market (SPY) | 1.5% | -3.4% |
| Sector (XLV) | 8.3% | -3.9% |
Fundamental Drivers
The -76.1% change in OTLK stock from 7/31/2025 to 2/11/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2112026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.96 | 0.47 | -76.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 1 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 15.7 | |
| Shares Outstanding (Mil) | 31 | 47 | -34.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2025 to 2/11/2026| Return | Correlation | |
|---|---|---|
| OTLK | -76.1% | |
| Market (SPY) | 9.8% | 6.7% |
| Sector (XLV) | 20.3% | 1.4% |
Fundamental Drivers
The -77.2% change in OTLK stock from 1/31/2025 to 2/11/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2112026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.06 | 0.47 | -77.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 1 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 15.7 | |
| Shares Outstanding (Mil) | 24 | 47 | -49.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2025 to 2/11/2026| Return | Correlation | |
|---|---|---|
| OTLK | -77.2% | |
| Market (SPY) | 16.0% | 11.8% |
| Sector (XLV) | 7.8% | 3.8% |
Fundamental Drivers
The -98.0% change in OTLK stock from 1/31/2023 to 2/11/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2112026 | Change |
|---|---|---|---|
| Stock Price ($) | 23.00 | 0.47 | -98.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 1 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 15.7 | |
| Shares Outstanding (Mil) | 11 | 47 | -76.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2023 to 2/11/2026| Return | Correlation | |
|---|---|---|
| OTLK | -98.0% | |
| Market (SPY) | 76.6% | 9.5% |
| Sector (XLV) | 22.6% | 5.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OTLK Return | 5% | -21% | -64% | -76% | -16% | -73% | -98% |
| Peers Return | 10% | -24% | -24% | 28% | 45% | 11% | 30% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 85% |
Monthly Win Rates [3] | |||||||
| OTLK Win Rate | 42% | 50% | 33% | 42% | 58% | 0% | |
| Peers Win Rate | 57% | 45% | 47% | 45% | 52% | 70% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| OTLK Max Drawdown | -28% | -36% | -81% | -82% | -55% | -75% | |
| Peers Max Drawdown | -20% | -40% | -46% | -29% | -35% | -7% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: REGN, AMGN, PFE, CHRS, KOD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/11/2026 (YTD)
How Low Can It Go
| Event | OTLK | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -93.8% | -25.4% |
| % Gain to Breakeven | 1525.7% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -61.9% | -33.9% |
| % Gain to Breakeven | 162.3% | 51.3% |
| Time to Breakeven | 146 days | 148 days |
| 2018 Correction | ||
| % Loss | -98.2% | -19.8% |
| % Gain to Breakeven | 5605.6% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to REGN, AMGN, PFE, CHRS, KOD
In The Past
Outlook Therapeutics's stock fell -93.8% during the 2022 Inflation Shock from a high on 2/8/2021. A -93.8% loss requires a 1525.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Outlook Therapeutics (OTLK)
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
AI Analysis | Feedback
- The official, FDA-approved version of Avastin for wet AMD.
- Like Allergan (Botox) repurposing a drug for a new approved indication, but with Avastin for wet AMD.
AI Analysis | Feedback
- ONS-5010 (LYTENAVAâ„¢ / bevacizumab-vikg): An investigational ophthalmic formulation of bevacizumab being developed for intravitreal injection to treat wet age-related macular degeneration (wet AMD).
AI Analysis | Feedback
Major Customers of Outlook Therapeutics (OTLK)
Outlook Therapeutics (OTLK) primarily sells its pharmaceutical products to other companies, specifically a limited number of wholesale drug distributors. These distributors, in turn, supply the products to healthcare providers such as ophthalmologists, retinal specialists, hospitals, and other clinics.
The major customer companies that Outlook Therapeutics anticipates working with for the commercialization of its product ONS-5010 (Lytensoâ„¢/bevacizumab-vikg) are:
- AmerisourceBergen Corporation (Symbol: ABC)
- Cardinal Health, Inc. (Symbol: CAH)
- McKesson Corporation (Symbol: MCK)
AI Analysis | Feedback
AGC Biologics (Parent: AGC Inc., TYO: 5201)
Ajinomoto Bio-Pharma Services (Parent: Ajinomoto Co., Inc., TYO: 2802)
Catalent, Inc. (NYSE: CTLT)
AI Analysis | Feedback
Bob Jahr Chief Executive Officer
Mr. Jahr brings over 20 years of experience in the biopharmaceutical industry, having built and led commercial teams across various therapeutic areas including rare disease, oncology, hematology, autoimmunology, neuroscience, cardiovascular, and inflammation. Throughout his career, he has overseen operational and commercial efforts for multiple billion-dollar assets and franchises. Prior to joining Outlook Therapeutics, Mr. Jahr served as the Chief Commercial Officer for Sobi North America (NA), where he was responsible for commercial strategy, planning, and execution, including marketing, sales, operations, and market access activities. At Sobi NA, he led the immunology and hematology franchises and three global development asset teams. He also held roles as General Manager & Vice President Head of International Markets and VP Head of US Payer Value, Pricing, Strategy & Innovation at UCB Pharma SA, and leadership positions in sales, marketing, operations, payer strategy, and market access at Amgen.
Lawrence A. Kenyon Executive Vice President, Chief Financial Officer, Treasurer, Secretary and Director
Mr. Kenyon has served as Outlook Therapeutics' Chief Financial Officer and Secretary since September 2015 and has been a member of its Board of Directors since August 2018. He also held the role of Interim Chief Executive Officer from December 2024 and previously served as President and CEO from August 2018 to July 2021. Before joining Outlook Therapeutics, Mr. Kenyon was the Chief Financial Officer of Arno Therapeutics, Inc., where he also served as Chief Operating Officer from July 2014 to September 2015. He was Interim President & Chief Executive Officer, Chief Financial Officer, and Secretary of Tamir Biotechnology, Inc., a publicly held biopharmaceutical company, from December 2011 to March 2013. From 2007 to 2009, he was Chief Financial Officer and Secretary of Alfacell Corporation, also serving at various times as Executive Vice President, Chief Operating Officer, President, and a board member. Earlier, from 2000 to 2006, Mr. Kenyon was Executive Vice President, Chief Financial Officer, and Corporate Secretary at NeoPharm, Inc., a publicly traded biopharmaceutical company.
Dr. Surendra Sharma M.D. Senior Vice President of Medical Affairs
Dr. Sharma brings more than 15 years of experience in the pharmaceutical and biotechnology industries. He has a track record of leading corporate alliances among research and development, commercial, marketing, and business stakeholders. Most recently, he was the Senior Medical Director, Cornea, Dry Eye and Retina, Global Medical Affairs at Santen Pharmaceuticals, Ltd. His career includes roles at companies such as Spark Therapeutics, Inc., Biogen Inc., Alcon Laboratories, Inc., and Regeneron Pharmaceuticals, Inc., where he directed global scientific communications strategies.
Dr. Jennifer M. Kissner Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs
Dr. Kissner serves as the Senior Vice President of Clinical Development and Regulatory Affairs at Outlook Therapeutics. Her professional background and experience contribute to the company's efforts in clinical trials and regulatory submissions for its ophthalmic treatments.
Jedd Comiskey Senior Vice President - Head of Europe
Mr. Comiskey is the Senior Vice President and Head of Europe for Outlook Therapeutics. In this role, he is responsible for the company's operations and strategic initiatives across the European market, particularly in light of regulatory approvals and planned commercial launches in the region.
AI Analysis | Feedback
The key risks to Outlook Therapeutics (OTLK) primarily revolve around regulatory challenges, financial stability, and the subsequent impact on its market valuation.
- Failure to Obtain FDA Approval for ONS-5010/LYTENAVAâ„¢: Outlook Therapeutics faces a significant and existential risk regarding its inability to secure full U.S. Food and Drug Administration (FDA) approval for its lead drug candidate, ONS-5010 (also known as LYTENAVAâ„¢), for treating wet age-related macular degeneration (wet AMD). The company has received multiple complete response letters (CRLs) from the FDA, citing insufficient evidence of effectiveness and, in prior instances, manufacturing and control issues. These regulatory setbacks have a direct and severe impact on the company's ability to access the lucrative U.S. market, which is crucial for its revenue generation and overall viability.
- Significant Financial Challenges and Liquidity Issues: Directly linked to the regulatory hurdles, Outlook Therapeutics is contending with substantial financial difficulties. The company's financial strength is rated as poor, characterized by a distressed Altman Z-Score, negative operating and net margins, minimal revenue, and high cash burn. These factors have led management to express "substantial doubt about the Company's ability to continue as a going concern," indicating potential liquidity issues and a pressing need for additional capital.
- High Stock Volatility and Speculative Nature: The company's stock is highly volatile and considered a speculative investment due to the uncertainties surrounding its regulatory approvals and financial health. The share price has experienced significant drops following FDA rejections, reflecting investor apprehension and the binary nature of the company's future, heavily dependent on a regulatory breakthrough.
AI Analysis | Feedback
The following are clear emerging threats for Outlook Therapeutics (OTLK):
- Emergence and increasing market penetration of biosimilars for existing market-leading anti-VEGF therapies, particularly Eylea (aflibercept). OTLK's ONS-5010 aims to be an on-label, potentially cost-effective alternative to existing treatments. However, the approval and launch of biosimilar versions of established and highly efficacious therapies like Lucentis (ranibizumab) and, imminently, Eylea, directly erode ONS-5010's primary value proposition by offering other FDA-approved, lower-cost options. This intensifies price competition and can diminish ONS-5010's market differentiation.
- Introduction and adoption of novel anti-VEGF therapies with extended dosing intervals. New therapies such as Vabysmo (faricimab), which targets both VEGF-A and Ang-2, offer significantly extended dosing intervals (up to every 4 months) compared to standard anti-VEGFs. This addresses a major unmet need for patient convenience and reduced treatment burden. As these therapies gain market share, the demand for drugs requiring more frequent injections, even with a potential cost advantage, may decrease, challenging OTLK's market opportunity for ONS-5010.
AI Analysis | Feedback
Outlook Therapeutics' main product is ONS-5010/LYTENAVA (bevacizumab-vikg), an ophthalmic formulation of bevacizumab, which is developed for retinal conditions including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).
The addressable markets for their main product are significant:
- The global anti-VEGF retina market is estimated to be over $15.9 billion.
- For the United States, the anti-VEGF retina market represents an opportunity of $8.5 billion. Specifically for wet AMD, the U.S. market size was approximately $2.6 billion in 2023, constituting about 33% of the 7 Major Markets (7MM) share, and is projected to grow at a CAGR of 6.6% by 2034.
- In the EU and UK markets, the anti-VEGF retina market indicates an opportunity of $3.6 billion. LYTENAVAâ„¢ (bevacizumab gamma) has received European Commission Marketing Authorization for wet AMD and is set for commercial launch in these regions in early 2025, with 10 years of market exclusivity.
- The wet AMD market size across the 7MM (7 Major Markets) was valued at $7.7 billion in 2023, with anticipated growth through 2034.
AI Analysis | Feedback
Outlook Therapeutics (OTLK): Key Revenue Growth Drivers for the Next 2-3 Years
Outlook Therapeutics (OTLK) is poised for significant revenue growth over the next 2-3 years, primarily driven by the commercialization and potential regulatory approvals of its ophthalmic formulation of bevacizumab, ONS-5010/LYTENAVA™. The key drivers include: * Commercial Launch of LYTENAVA™ in Europe and the UK Outlook Therapeutics has already secured marketing authorization for LYTENAVA™ (bevacizumab gamma) in the European Union and the United Kingdom for the treatment of wet age-related macular degeneration (wet AMD). The company is actively preparing for a commercial launch in these regions, expected in the first half of 2025. Initial sales into Germany and the UK have already begun contributing to revenue in the third fiscal quarter of 2025. This strategic market entry is expected to be a crucial immediate driver of revenue. * Potential FDA Approval and US Market Entry for ONS-5010/LYTENAVA™ A significant driver of future revenue hinges on the potential approval and subsequent launch of ONS-5010/LYTENAVA™ in the United States. Outlook Therapeutics plans to resubmit its Biologics License Application (BLA) to the FDA in the first quarter of 2025, with an anticipated approval in the third quarter of 2025, and a PDUFA goal date set for August 27, 2025. If approved, ONS-5010/LYTENAVA™ would be the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications, including wet AMD, and would benefit from 12 years of regulatory exclusivity. The U.S. market for wet AMD alone represents a multi-billion dollar opportunity. * Disruptive Pricing Strategy and Market Position LYTENAVA™ is strategically positioned as a more affordable, approved treatment option for wet AMD compared to existing branded products like Roche's Lucentis® and Novartis' Eylea®, as well as the off-label use of repackaged Avastin®. The company anticipates that its product will be compared to other approved treatments, not off-label alternatives, for pricing considerations. This competitive pricing strategy, combined with a decade of market exclusivity in Europe and potential exclusivity in the US, could enable OTLK to capture significant market share. * Expansion into Additional Retinal Indications While the immediate focus is on wet AMD, Outlook Therapeutics has indicated a longer-term potential to expand the use of ONS-5010/LYTENAVA™ into other retinal diseases, such as diabetic macular edema (DME) and branch retinal vein occlusion (BRVO). Successful expansion into these additional indications would broaden the product's market reach and provide further avenues for sustained revenue growth beyond the initial wet AMD launch.AI Analysis | Feedback
Share Issuance
- In May 2025, Outlook Therapeutics priced a $13.0 million public offering, consisting of 9,285,714 shares of common stock at $1.40 per share, with each share including warrants to purchase two additional shares. The proceeds are intended for working capital and general corporate purposes.
- The company has engaged in capital management activities, including an At-the-Market Sales Agreement with BTIG to issue and sell shares of common stock up to $100 million.
- Outlook Therapeutics completed private placements raising $60.3 million and issued convertible promissory notes.
Inbound Investments
- Outlook Therapeutics has entered into a strategic commercialization agreement with Cencora (formerly AmerisourceBergen) to expand its reach for connecting to retina specialists and their patients, particularly in anticipation of potential FDA approval for ONS-5010. Cencora will provide third-party logistics (3PL) services, distribution, and pharmacovigilance in the United States.
- In 2024, the company formed a collaboration with Cencora to support the commercial launch of ONS-5010/LYTENAVA in the EU and UK.
Capital Expenditures
- Outlook Therapeutics reported $0.00 in capital expenditures in the last 12 months, resulting in a free cash flow of -$56.43 million.
- The company's income statement indicates a net loss of $(75.4) million for the fiscal year ended September 30, 2024, reflecting increased research and development expenses.
- Outlook Therapeutics is focused on the development and commercialization of ONS-5010/LYTENAVA, with strategic efforts to secure regulatory approvals in the EU, UK, and the US, and is conducting additional clinical trials to address FDA requirements, which are a primary focus of its expenditures.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Outlook Therapeutics Earnings Notes | 12/16/2025 | |
| How Low Can Outlook Therapeutics Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 25.32 |
| Mkt Cap | 40.8 |
| Rev LTM | 7,310 |
| Op Inc LTM | 1,817 |
| FCF LTM | 1,857 |
| FCF 3Y Avg | 1,801 |
| CFO LTM | 2,464 |
| CFO 3Y Avg | 2,305 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.2% |
| Rev Chg 3Y Avg | 8.5% |
| Rev Chg Q | 7.5% |
| QoQ Delta Rev Chg LTM | 0.7% |
| Op Mgn LTM | 24.1% |
| Op Mgn 3Y Avg | 22.4% |
| QoQ Delta Op Mgn LTM | 0.6% |
| CFO/Rev LTM | 20.8% |
| CFO/Rev 3Y Avg | 25.8% |
| FCF/Rev LTM | 16.5% |
| FCF/Rev 3Y Avg | 20.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 40.8 |
| P/S | 5.5 |
| P/EBIT | 8.0 |
| P/E | 8.8 |
| P/CFO | 5.8 |
| Total Yield | 6.1% |
| Dividend Yield | 0.2% |
| FCF Yield 3Y Avg | -24.5% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.5% |
| 3M Rtn | 11.5% |
| 6M Rtn | 33.9% |
| 12M Rtn | 22.6% |
| 3Y Rtn | -10.4% |
| 1M Excs Rtn | 7.0% |
| 3M Excs Rtn | 15.8% |
| 6M Excs Rtn | 27.8% |
| 12M Excs Rtn | 7.3% |
| 3Y Excs Rtn | -80.7% |
Price Behavior
Price Behavior
| Market Price | $0.47 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 06/14/2016 | |
| Distance from 52W High | -84.2% | |
| 50 Days | 200 Days | |
| DMA Price | $1.15 | $1.51 |
| DMA Trend | down | down |
| Distance from DMA | -59.3% | -68.8% |
| 3M | 1YR | |
| Volatility | 159.8% | 123.6% |
| Downside Capture | -225.22 | 73.62 |
| Upside Capture | -761.62 | -66.65 |
| Correlation (SPY) | -9.4% | 11.7% |
OTLK Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -1.75 | -1.05 | -1.29 | 0.62 | 0.70 | 0.77 |
| Up Beta | 13.11 | 2.95 | 1.43 | 4.77 | 1.05 | 0.92 |
| Down Beta | 2.28 | 4.84 | 1.77 | 1.86 | 0.83 | 0.90 |
| Up Capture | -1339% | -742% | -384% | -162% | -35% | -5% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 6 | 14 | 27 | 59 | 115 | 341 |
| Down Capture | 152% | 79% | -158% | 20% | 85% | 107% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 14 | 27 | 33 | 64 | 125 | 382 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OTLK | |
|---|---|---|---|---|
| OTLK | -74.6% | 123.3% | -0.37 | - |
| Sector ETF (XLV) | 8.3% | 17.3% | 0.30 | 4.4% |
| Equity (SPY) | 15.5% | 19.3% | 0.62 | 12.0% |
| Gold (GLD) | 75.7% | 24.9% | 2.23 | -2.0% |
| Commodities (DBC) | 8.8% | 16.6% | 0.34 | 1.6% |
| Real Estate (VNQ) | 6.0% | 16.6% | 0.18 | 5.6% |
| Bitcoin (BTCUSD) | -29.3% | 44.7% | -0.64 | 8.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OTLK | |
|---|---|---|---|---|
| OTLK | -58.7% | 112.1% | -0.10 | - |
| Sector ETF (XLV) | 7.9% | 14.5% | 0.36 | 9.7% |
| Equity (SPY) | 13.9% | 17.0% | 0.65 | 15.7% |
| Gold (GLD) | 22.9% | 16.9% | 1.10 | 5.4% |
| Commodities (DBC) | 11.4% | 18.9% | 0.49 | 6.4% |
| Real Estate (VNQ) | 5.1% | 18.8% | 0.18 | 10.5% |
| Bitcoin (BTCUSD) | 13.3% | 57.9% | 0.45 | 11.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OTLK | |
|---|---|---|---|---|
| OTLK | -52.1% | 119.8% | -0.02 | - |
| Sector ETF (XLV) | 10.8% | 16.5% | 0.54 | 7.4% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 11.4% |
| Gold (GLD) | 15.7% | 15.5% | 0.85 | 2.1% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 5.0% |
| Real Estate (VNQ) | 6.1% | 20.7% | 0.26 | 8.4% |
| Bitcoin (BTCUSD) | 68.7% | 66.7% | 1.08 | 4.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 12/19/2025 | -2.9% | -12.1% | -75.6% |
| 8/14/2025 | -3.7% | -0.8% | -56.8% |
| 5/15/2025 | 4.5% | -2.1% | 5.7% |
| 12/27/2024 | 18.2% | 31.8% | 17.1% |
| 8/14/2024 | -5.3% | -8.4% | -16.3% |
| 5/15/2024 | -1.3% | 7.7% | 3.2% |
| 12/22/2023 | 5.4% | -7.1% | 2.8% |
| 8/14/2023 | -1.3% | -12.7% | -85.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 9 | 10 |
| # Negative | 9 | 9 | 8 |
| Median Positive | 5.4% | 7.7% | 9.8% |
| Median Negative | -2.9% | -7.1% | -43.7% |
| Max Positive | 18.2% | 35.8% | 61.6% |
| Max Negative | -10.3% | -19.2% | -85.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 12/19/2025 | 10-K |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 02/14/2025 | 10-Q |
| 09/30/2024 | 12/27/2024 | 10-K |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 02/14/2024 | 10-Q |
| 09/30/2023 | 12/22/2023 | 10-K |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 02/14/2023 | 10-Q |
| 09/30/2022 | 12/29/2022 | 10-K |
| 06/30/2022 | 08/10/2022 | 10-Q |
| 03/31/2022 | 05/13/2022 | 10-Q |
| 12/31/2021 | 02/14/2022 | 10-Q |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.